1 Guidance
1.1 Vinflunine is not recommended within its marketing authorisation for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract that has progressed after treatment with platinum-based chemotherapy.
1.2 People currently receiving vinflunine that is not recommended according to 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.